Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025

Ogkologos - 7 Μαΐου, 2025

Will This Cancer Metastasize? Check Its “Stickiness”

Ogkologos - 6 Μαΐου, 2025

Utility of Genomic Profiling Use for Targeted Therapy in a Phase...

Ogkologos - 6 Μαΐου, 2025

InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of...

Ogkologos - 5 Μαΐου, 2025

FDA Approval Likely to Change Initial Treatment for Some People with...

Ogkologos - 2 Μαΐου, 2025

FDA Approves Durvalumab for Muscle Invasive Bladder Cancer

Ogkologos - 2 Μαΐου, 2025

EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin

Ogkologos - 30 Απριλίου, 2025

A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically...

Ogkologos - 30 Απριλίου, 2025

Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention...

Ogkologos - 29 Απριλίου, 2025

Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients...

Ogkologos - 28 Απριλίου, 2025

1...505152...440 Σελίδα 51 από 440

MOST POPULAR

Maintenance Therapy Delays Cancer Growth for People With Advanced or Recurrent...

24 Ιουλίου, 2023

FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate...

15 Απριλίου, 2022

Real-World Increase in Biomarker Testing in Lung Cancer Patients, Registry Study...

23 Μαρτίου, 2022

Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic...

25 Μαρτίου, 2021

Φόρτωση περισσοτέρων

ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025

Will This Cancer Metastasize? Check Its “Stickiness”

Utility of Genomic Profiling Use for Targeted Therapy in a Phase...

InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of...

FDA Approval Likely to Change Initial Treatment for Some People with...

FDA Approves Durvalumab for Muscle Invasive Bladder Cancer

EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin

A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically...

Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention...

Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients...

MOST POPULAR

Maintenance Therapy Delays Cancer Growth for People With Advanced or Recurrent...

FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate...

Real-World Increase in Biomarker Testing in Lung Cancer Patients, Registry Study...

Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic...

HOT NEWS

FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma

Advances in Treating Kidney Cancer and Metastatic Prostate Cancer: Research from...

November is National Family Caregivers Month

Here’s Why We’re Building Pet-Friendly Domestic Violence Shelters–And How You Can...

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ